Where to buy ruxolitinib cream (Opzelura) and guide to regular purchasing channels

Ruxolitinib cream (Opzelura, scientific name: Ruxolitinib cream) is a topical JAK inhibitor, mainly used to treat non-segmental vitiligo and mild to moderate atopic dermatitis. At present, the drug has been approved and marketed in countries such as Europe and the United States, but it has not yet been marketed in China. Therefore, patients are temporarily unable to purchase drugs through formal channels through domestic hospital pharmacies or retail pharmacies.

For patients with clear medication needs, they usually need to choose original drugs through regular overseas pharmacies or cross-border medical institutions. The price of foreign original drugs is relatively high, with one dose often costing more than 10,000 yuan. Although the cost of this channel is high, the quality of the drugs is guaranteed and they can ensure that they are consistent with the drugs used in clinical studies. It is recommended that patients be sure to verify pharmacy qualifications when choosing channels and avoid purchasing products from unknown sources.

In addition to expensive original drugs, generic drugs produced in some countries have also appeared in overseas markets. Among them, Bangladesh version of generic drugs are more affordable, with a drug costing about a few hundred yuan. Since their ingredients are basically the same as the original drugs, generic drugs provide a viable alternative for patients who require long-term medication but have a greater financial burden. However, patients should obtain them through formal channels to ensure reliable sources of drugs and avoid the risks caused by using inferior generic drugs.

Generally speaking, ruxolitinib cream is currently mainly obtained through overseas channels. Patients should consult a doctor before purchasing to confirm whether their condition is suitable for using the drug, and follow the doctor's instructions to formulate a medication plan. At the same time, attention should be paid to verifying the legality and formality of the purchasing channels to avoid choosing non-compliant channels due to low prices. With the future review progress of this drug in China, it is expected that patient accessibility will gradually improve and regular drug use opportunities will be provided for more patients.

Reference materials:https://www.drugs.com/